We are a global bioscience company dedicated to healthy aging.

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors.

Key Investment Highlights:


1 PROVEN AND PROPRIETARY NAD+ BOOSTING SUPPLEMENT

  • Total 2020 net sales of $59 million with $47 million of Tru Niagen® net sales
  • Tru Niagen® is the most efficient way to safely elevate NAD+
  • Safety profile backed by 13 clinical trials and global regulatory approvals
  • Strong IP protection with 25+ owned or licensed patents
  • $75MM+ of third-party research on Niagen®

2 SIGNIFICANT OPPORTUNITY DRIVEN BY TRENDS IN HEALTH & WELLNESS

  • Global anti-aging market of ~$410 billion with dietary supplements growing 6%(1)
  • Tru Niagen® gaining share in healthy aging and fitness categories; potential to expand to larger addressable markets
  • Exploring adjacent categories for Niagen® such as pet and infant nutrition

(1)ChromaDex estimates.  See latest Investor Presentation for details

3 EXPANDING GLOBAL DISTRIBUTION AND INTRODUCING NEW PRODUCTS

  • E-commerce represents ~60% of the business today, including North America, Europe, and Asia
  • Expanded to UK and Australia in 2020
  • Launched in Walmart U.S. in June 2021
  • Strong blue-chip partners include A.S. Watson, Nestlé Health Science and W.R. Grace, and two new partners in 2021 in H&H Group and Ro



4 STRONG MOMENTUM AND FINANCIAL DISCIPLINE

  • Revenue CAGR of ~40% and gross margin increase from 48% to 60%+ since strategic pivot to focus on consumer product, Tru Niagen®(2)
  • Approaching cash flow break-even, as measured by Adjusted EBITDA excluding total legal expense(3)
  • Investing in brand building and R&D in 2021 given rapid growth in NAD+ market

(2) Period from Q1 2017 to Q2 2021. Quarterly sales.
(3) Non-GAAP metric.

Build a Global Brand

In March 2017 ChromaDex began a strategic shift from an ingredient and testing company with the long-term goal of building its new consumer product, TRU NIAGEN®, into a global brand. The company has since expanded retail distribution into four new international markets and has signed supply agreements with strong global partners, including Nestlé Health Science and A.S. Watson Group. (See link to Nestlé Health Science press release) and (See link to latest A.S. Watson Group press release)

Own the Science

As a leader in the growing field of NR and NAD research, ChromaDex continues to build upon and protect its intellectual property, invest in quality research, partner with the world's leading scientists, and educate consumers on the health benefits of NR. (Notable Scientific Research) (Patent Portfolio)

ChromaDex has a strong patent portfolio around TRU NIAGEN®, with over 16 licensed global patents or patents pending. The lead patent is one that is exclusively licensed from Dartmouth. In September 2018, ChromaDex and the Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. (“Elysium”). The complaint alleges that Elysium’s BASIS® dietary supplement violates patents that cover compositions containing isolated nicotinamide riboside (“NR”) held by Dartmouth and licensed exclusively to ChromaDex. (See link to Elysium related litigation)

Focus on Fundamentals

ChromaDex is committed to being a fundamentally sound, principled business operation focused on the long-term. The company continues to build a world class team with greater depth in brand reputation, communications, science, regulatory and sales.

ChromaDex recently secured regulatory approvals from the EU and Australia, which includes five-, and two-year exclusivity, respectively. This continues an unprecedented streak of successful regulatory acceptance of NR, a key point of differentiation from any other novel NAD precursors.

It is the company’s mission to lead by example in this industry. ChromaDex Co-Founder and Chairman, Frank Jaksch, is a Board Member of the Natural Products Association, and ChromaDex Chief Executive Officer, Rob Fried, is a Board Member of the Council for Responsible Nutrition.

For more than 20 years, and through a transition from an ingredients business to a direct-to-consumer dietary supplements company, we have remained true to our commitment to innovation, science and safety.

See What's New...

Latest News

Latest Annual Filings

Latest Quarterly Results

Latest Presentation